✦ LIBER ✦

MK-0767, a novel dual PPARα/γ agonist, displays robust antihyperglycemic and hypolipidemic activities

✍ Scribed by Thomas W Doebber; Linda J Kelly; Gaochao Zhou; Roger Meurer; Chhabi Biswas; Ying Li; Margaret S Wu; Marc C Ippolito; Yu-Sheng Chao; Pei-Ran Wang; Samuel D Wright; David E Moller; Joel P Berger

Book ID: 116288334
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 261 KB
Volume: 318
Category: Article
ISSN: 0006-291X
DOI: 10.1016/j.bbrc.2004.04.032

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Novel Tricyclic-α-alkyloxyphenylpropioni

Novel Tricyclic-α-alkyloxyphenylpropionic Acids: Dual PPARα/γ Agonists with Hypolipidemic and Antidiabetic Activity

✍ Sauerberg, Per; Pettersson, Ingrid; Jeppesen, Lone; Bury, Paul S.; Mogensen, Joh 📂 Article 📅 2002 🏛 American Chemical Society 🌐 English ⚖ 394 KB

Novel Tricyclic α-Alkoxyphenyl Propanoic

Novel Tricyclic α-Alkoxyphenyl Propanoic Acid Derivatives: Dual PPAR α/γ Agonists with Hypolipidemic and Antidiabetic Activity

✍ Mitchell A. Avery; Amar Chittiboyina; Akshay Patny 📂 Article 📅 2004 🏛 John Wiley and Sons ⚖ 61 KB

(2 R )-2-Ethylchromane-2-carboxylic Acid

(2 R )-2-Ethylchromane-2-carboxylic Acids: Discovery of Novel PPARα/γ Dual Agonists as Antihyperglycemic and Hypolipidemic Agents

✍ Koyama, Hiroo; Miller, Daniel J.; Boueres, Julia K.; Desai, Ranjit C.; Jones, A. 📂 Article 📅 2004 🏛 American Chemical Society 🌐 English ⚖ 153 KB

Design and Synthesis of α-Aryloxyphenyla

Design and Synthesis of α-Aryloxyphenylacetic Acid Derivatives: A Novel Class of PPARα/γ Dual Agonists with Potent Antihyperglycemic and Lipid Modulating Activity

✍ Shi, Guo Q.; Dropinski, James F.; McKeever, Brian M.; Xu, Shihua; Becker, Joseph 📂 Article 📅 2005 🏛 American Chemical Society 🌐 English ⚖ 287 KB

[14C] and [3H]-labelling of Ragaglitazar

[14C] and [3H]-labelling of Ragaglitazar: A dual acting PPARα and PPARγ agonist with hypolipidemic and anti-diabetic activity

✍ Jesper B. Kristensen; Steen K. Johansen; Jacob S. Valsborg; Lars Martiny; Christ 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 138 KB

## Abstract Currently, Ragaglitazar is being developed as a drug for the treatment of hyperglycaemia and hyperlipidemia in patients with type 2 diabetes. Here, we report the labelling of Ragaglitazar with carbon‐14 and tritium for in vivo and in vitro investigations. Two different carbon‐14 labelle